JP2019514970A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514970A5
JP2019514970A5 JP2018558199A JP2018558199A JP2019514970A5 JP 2019514970 A5 JP2019514970 A5 JP 2019514970A5 JP 2018558199 A JP2018558199 A JP 2018558199A JP 2018558199 A JP2018558199 A JP 2018558199A JP 2019514970 A5 JP2019514970 A5 JP 2019514970A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antimetabolite
individual
bladder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018558199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514970A (ja
JP7712055B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/031445 external-priority patent/WO2017193098A1/en
Publication of JP2019514970A publication Critical patent/JP2019514970A/ja
Publication of JP2019514970A5 publication Critical patent/JP2019514970A5/ja
Priority to JP2021172052A priority Critical patent/JP2022009327A/ja
Priority to JP2023206570A priority patent/JP2024028881A/ja
Application granted granted Critical
Publication of JP7712055B2 publication Critical patent/JP7712055B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018558199A 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法 Active JP7712055B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021172052A JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662333151P 2016-05-06 2016-05-06
US62/333,151 2016-05-06
US201762443614P 2017-01-06 2017-01-06
US62/443,614 2017-01-06
PCT/US2017/031445 WO2017193098A1 (en) 2016-05-06 2017-05-05 Method of treating lower tract urothelial cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021172052A Division JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2019514970A JP2019514970A (ja) 2019-06-06
JP2019514970A5 true JP2019514970A5 (enExample) 2020-06-18
JP7712055B2 JP7712055B2 (ja) 2025-07-23

Family

ID=60203435

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018558199A Active JP7712055B2 (ja) 2016-05-06 2017-05-05 下部尿路上皮がんを処置する方法
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Pending JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021172052A Withdrawn JP2022009327A (ja) 2016-05-06 2021-10-21 下部尿路上皮がんを処置する方法
JP2023206570A Pending JP2024028881A (ja) 2016-05-06 2023-12-07 下部尿路上皮がんを処置する方法

Country Status (23)

Country Link
US (1) US20190388338A1 (enExample)
EP (2) EP3452053B1 (enExample)
JP (3) JP7712055B2 (enExample)
KR (2) KR20220123317A (enExample)
CN (2) CN109475571A (enExample)
AU (1) AU2017261371B2 (enExample)
CA (1) CA3023274A1 (enExample)
ES (1) ES2940227T3 (enExample)
FI (1) FI3452053T3 (enExample)
HR (1) HRP20221544T1 (enExample)
HU (1) HUE060965T2 (enExample)
IL (2) IL295592A (enExample)
LT (1) LT3452053T (enExample)
MX (2) MX389296B (enExample)
NZ (3) NZ787786A (enExample)
PL (1) PL3452053T3 (enExample)
PT (1) PT3452053T (enExample)
RS (1) RS64032B1 (enExample)
RU (2) RU2022100624A (enExample)
SG (2) SG10201913416PA (enExample)
SI (1) SI3452053T1 (enExample)
SM (1) SMT202300047T1 (enExample)
WO (1) WO2017193098A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
WO2019023388A1 (en) * 2017-07-25 2019-01-31 Taris Biomedical Llc METHODS OF TREATING TUMOR METASTASIS
PE20210041A1 (es) * 2017-11-08 2021-01-08 Taris Biomedical Llc Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US8343516B2 (en) 2009-06-26 2013-01-01 Taris Biomedical, Inc. Solid drug tablets for implantable drug delivery devices
US8679094B2 (en) 2009-12-17 2014-03-25 Taris Biomedical, Inc. Implantable device with intravesical tolerability and methods of treatment
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
PT2600800T (pt) 2010-08-05 2020-11-05 Taris Biomedical Llc Dispositivo de administração de drogas por stent ureteral, kit e método
WO2012106714A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
US20150216937A1 (en) * 2012-03-29 2015-08-06 Altor Bioscience Corporation Methods for treating neoplasia
KR102383496B1 (ko) 2012-08-31 2022-04-08 타리스 바이오메디컬 엘엘씨 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법
RU2657591C2 (ru) * 2012-08-31 2018-06-14 ТАРИС Биомедикал ЛЛК Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения
JP2016508842A (ja) 2013-03-05 2016-03-24 タリス バイオメディカル エルエルシー 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法
EP2968120A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices and methods for drug delivery
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2015026813A1 (en) 2013-08-19 2015-02-26 Taris Biomedical Llc Multi-unit drug delivery devices and methods
HRP20251264T1 (hr) * 2014-03-06 2025-12-05 Taris Biomedical Llc Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
KR102391761B1 (ko) 2014-06-26 2022-04-27 타리스 바이오메디컬 엘엘씨 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods

Similar Documents

Publication Publication Date Title
Lee et al. Immune checkpoint inhibitors in 10 years: contribution of basic research and clinical application in cancer immunotherapy
JP2019514970A5 (enExample)
US10076528B2 (en) System and method for diagnosis and treatment
Antonia et al. Immuno-oncology combinations: a review of clinical experience and future prospects
Pramyothin et al. Vitamin D in adipose tissue and serum 25‐hydroxyvitamin D after roux‐en‐Y gastric bypass
JP2019522657A5 (enExample)
RU2022100624A (ru) Способ лечения рака уротелия нижних путей
Shaikh et al. Engineering stent based delivery system for esophageal cancer using docetaxel
Denlinger et al. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers
Hoag et al. Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review
Coloma et al. High incidence of cetuximab-related infusion reactions in head and neck patients
CN101612141B (zh) 丁丙诺啡贴剂
CN119923256A (zh) 包含大麻素的连续递送系统及其医药用途
Komarnitsky et al. P1. 04-006 rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following 1st line chemotherapy
Knight et al. Graft survival and immune regulation of pancreas allograft recipients induced with thymoglobulin, sirolimus, and cyclosporine
Islam et al. Marital Status and Survival in Patients with Multiple Myeloma: The Role of Marriage in the Management of Multiple Myeloma
El Akkawi et al. Systematic Review with Meta-analysis: Denosumab in Gluco-corticoids Induced Osteoporosis
Seminario-Vidal et al. 283 Toxic epidermal necrolysis in the setting of acute graft-versus-host disease successfully treated with tumor necrosis factor alpha inhibitors
Vidal et al. Legionella in a patient with rheumatoid arthritis receiving abatacept
HK40005970A (en) Method of treating lower tract urothelial cancer
HK40044298A (en) Microbiome related immunotherapies
Wardley et al. Zometa®(zoledronic acid) in patients with skeletal metastases secondary to breast cancer—a study of home versus hospital administration
JPWO2021161032A5 (enExample)